Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPH4102 in Relapsed/Refractory CTCL
NCT02593045Phase 1Completed
- Sponsor
- Innate Pharma
- Start
- Oct 2015
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of lacutamab in cutaneous T-cell lymphoma (CTCL), sponsored by Innate Pharma. Primary endpoint: Occurrence of Dose Limiting Toxicities at 2 weeks. Started Oct 2015; status: completed.
02
Drugs
lacutamab
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02593045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593045.